-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Abstract: Weibo Cai from the University of Wisconsin, Kang Lei from Peking University First Hospital and their collaborators labelled 89Zr and 177Lu on the CD38-targeting monoclonal antibody darlimumab, which can not only monitor the CD38 expression of living tumors by PET imaging Moreover, one administration after labeling with 177Lu can significantly inhibit the growth of CD38-positive lymphoma, providing an effective candidate for clinical diagnosis and treatment in the future.
Keywords: Advanced Science, daratumumab, CD38, immuno-PET, radioimmunotherapy Lymphoma is a highly heterogeneous malignant tumor originating from the lymphoid hematopoietic system, clinical manifestations, prognosis, histological type and clinical Staging is closely related.
At present, in the clinic, the targeted therapy of lymphoma mostly focuses on the CD20 surface antigen, but some patients with lymphoma that do not express CD20 cannot benefit.
CD38 is a type II transmembrane glycoprotein with a molecular weight of about 45 kDa.
It is highly expressed in 95-100% of malignant plasma cells, while its expression level is relatively low in normal cells.
Daratumumab is the first human monoclonal antibody targeting CD38 approved by the US FDA for the treatment of refractory/relapsed multiple myeloma.
Weibo Cai of the University of Wisconsin-Madison and the research group of Kang Lei of Peking University First Hospital have implemented radioimmunotherapy research on lymphoma tumor models by labeling them with radionuclides.
The peak uptake of 89Zr-labeled daralimumab in CD38-positive tumors reached 19.
7 ± 2.
6 %ID/g, and 177Lu-labeled daralimumab can effectively inhibit lymphoma by inducing cell apoptosis, with high safety and low efficacy.
The injection dose is related to the degree of tumor uptake.
The team's research shows that CD38 is a new type of lymphoma biomarker with great application potential.
The 89Zr and 177Lu labeled daralimumab have played a good role in immune PET imaging and radioimmunotherapy in mouse lymphoma models.
It is expected to realize the clinical transformation of CD38 targeted drugs in the future and provide early specificity for lymphoma patients The results of sexual diagnosis and multiple treatments are published in Advanced Science.
Associate Professor Kang Lei and Associate Chief Physician of Peking University First Hospital are the first and co-corresponding authors of the study.
Researcher Xu Xiaojie from Beijing Institute of Bioengineering and Professor David Jiang from Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology are co-corresponding authors.
McGrady, University of Wisconsin, USA Professor Weibo Cai from the University of California is the corresponding author.
The above-mentioned research work has been supported by the NIH project of the United States (P30CA014520), the National Natural Science Foundation of China (81871385, 81822037, 81972446), the Outstanding Youth Project of the Beijing Natural Science Foundation (JQ19028), the Peking University Clinical Medicine + X Youth Project (PKU2020LCXQ007), China Supported by the Open Fund of the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Academy of Sciences (2020KF-01).
WILEY paper information: CD38-targeted theranostics of lymphoma with 89Zr/177Lu-labeled daratumumabLei Kang, Cuicui Li, Zachary T.
Rosenkrans, Nan Huo, Zhao Chen, Emily B.
Ehlerding, Yan Huo, Carolina A.
Ferreira, Todd E.
Barnhart , Jonathan W.
Engle, Rongfu Wang, Dawei Jiang, Xiaojie Xu, Weibo Cai Advanced Science DOI: 10.
1002/advs.
202001879 Click "Read the original text" in the lower left corner to view the original text of the paper. Introduction to AdvancedScience Journal "Advanced Science" (Advanced Science) Wiley's high-quality open source journal founded in 2014, publishes innovative achievements and cutting-edge progress in materials science, physical chemistry, biomedicine, engineering and other fields.
The journal is dedicated to disseminating scientific research results to the public to the greatest extent, and all articles are freely available.
The latest impact factor is 15.
840, and the 2020 SCI journals of the Chinese Academy of Sciences will be divided into the Q1 area of the material science category and the Q1 area of the engineering technology category.
Press and hold the QR code on the official WeChat platform of AdvancedScienceNewsWiley's scientific research information.
Follow us to share cutting-edge information｜Focus on scientific research trends to publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
com
Keywords: Advanced Science, daratumumab, CD38, immuno-PET, radioimmunotherapy Lymphoma is a highly heterogeneous malignant tumor originating from the lymphoid hematopoietic system, clinical manifestations, prognosis, histological type and clinical Staging is closely related.
At present, in the clinic, the targeted therapy of lymphoma mostly focuses on the CD20 surface antigen, but some patients with lymphoma that do not express CD20 cannot benefit.
CD38 is a type II transmembrane glycoprotein with a molecular weight of about 45 kDa.
It is highly expressed in 95-100% of malignant plasma cells, while its expression level is relatively low in normal cells.
Daratumumab is the first human monoclonal antibody targeting CD38 approved by the US FDA for the treatment of refractory/relapsed multiple myeloma.
Weibo Cai of the University of Wisconsin-Madison and the research group of Kang Lei of Peking University First Hospital have implemented radioimmunotherapy research on lymphoma tumor models by labeling them with radionuclides.
The peak uptake of 89Zr-labeled daralimumab in CD38-positive tumors reached 19.
7 ± 2.
6 %ID/g, and 177Lu-labeled daralimumab can effectively inhibit lymphoma by inducing cell apoptosis, with high safety and low efficacy.
The injection dose is related to the degree of tumor uptake.
The team's research shows that CD38 is a new type of lymphoma biomarker with great application potential.
The 89Zr and 177Lu labeled daralimumab have played a good role in immune PET imaging and radioimmunotherapy in mouse lymphoma models.
It is expected to realize the clinical transformation of CD38 targeted drugs in the future and provide early specificity for lymphoma patients The results of sexual diagnosis and multiple treatments are published in Advanced Science.
Associate Professor Kang Lei and Associate Chief Physician of Peking University First Hospital are the first and co-corresponding authors of the study.
Researcher Xu Xiaojie from Beijing Institute of Bioengineering and Professor David Jiang from Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology are co-corresponding authors.
McGrady, University of Wisconsin, USA Professor Weibo Cai from the University of California is the corresponding author.
The above-mentioned research work has been supported by the NIH project of the United States (P30CA014520), the National Natural Science Foundation of China (81871385, 81822037, 81972446), the Outstanding Youth Project of the Beijing Natural Science Foundation (JQ19028), the Peking University Clinical Medicine + X Youth Project (PKU2020LCXQ007), China Supported by the Open Fund of the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Academy of Sciences (2020KF-01).
WILEY paper information: CD38-targeted theranostics of lymphoma with 89Zr/177Lu-labeled daratumumabLei Kang, Cuicui Li, Zachary T.
Rosenkrans, Nan Huo, Zhao Chen, Emily B.
Ehlerding, Yan Huo, Carolina A.
Ferreira, Todd E.
Barnhart , Jonathan W.
Engle, Rongfu Wang, Dawei Jiang, Xiaojie Xu, Weibo Cai Advanced Science DOI: 10.
1002/advs.
202001879 Click "Read the original text" in the lower left corner to view the original text of the paper. Introduction to AdvancedScience Journal "Advanced Science" (Advanced Science) Wiley's high-quality open source journal founded in 2014, publishes innovative achievements and cutting-edge progress in materials science, physical chemistry, biomedicine, engineering and other fields.
The journal is dedicated to disseminating scientific research results to the public to the greatest extent, and all articles are freely available.
The latest impact factor is 15.
840, and the 2020 SCI journals of the Chinese Academy of Sciences will be divided into the Q1 area of the material science category and the Q1 area of the engineering technology category.
Press and hold the QR code on the official WeChat platform of AdvancedScienceNewsWiley's scientific research information.
Follow us to share cutting-edge information｜Focus on scientific research trends to publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
com
